Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01761123 · ClinicalTrials.gov registry record · Phase 1
Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum
A Phase 1 study of Seasonal Influenza, sponsored by Vaxart.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT01761123 is a Phase 1 study of Seasonal Influenza that has completed, run by Vaxart. The registered enrollment target is 37 participants, below the 438-participant average among 3 other Seasonal Influenza trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01761123, a Phase 1 study of Seasonal Influenza, has completed, sponsored by Vaxart.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
the purpose of the study is to determine the safety and tolerability of VXA-A1.1, an adjuvanted adenoviral based influenza vaccine, when delivery is targeted to the ileum, using a radio controlled capsule. The secondary objective is to evaluate the immune response (cellular and humoral) of two doses of VXA-A1.1 oral vaccine.
Conditions Studied
Interventions
- BIOLOGICAL VXA-A1.1
Study Locations (1)
Kentucky
- Scintipharma - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01761123
The ClinicalTrials.gov registry entry for NCT01761123 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 438-participant average among 3 other Seasonal Influenza trials with a reported enrollment target (92% lower). The listed sponsor is Vaxart, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Seasonal Influenza appearing as the primary indexed condition, and to 1 intervention - of which VXA-A1.1 is the first listed.
NCT01761123 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT01761123 about?
NCT01761123 is a clinical study titled "Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum". the purpose of the study is to determine the safety and tolerability of VXA-A1.1, an adjuvanted adenoviral based influenza vaccine, when delivery is targeted to the ileum, using a radio controlled capsule. The secondary objective is to evaluate the immune response (cellular and humoral) of two doses...
What is the current status of trial NCT01761123?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2013-01. Estimated completion is 2014-10.
What conditions does trial NCT01761123 study?
This clinical trial studies the following conditions: Seasonal Influenza.
What interventions are being tested in trial NCT01761123?
The interventions under investigation include: VXA-A1.1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01761123?
This trial is sponsored by Vaxart, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01761123 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seasonal Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults
RECRUITING · Phase 1
-
A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults
COMPLETED · Phase 1
-
A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.